drugset / Press release
European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
2023-10-31 · Ono Pharmaceutical Co., Ltd. · original ono-pharma.com ↗
This material is intended to notify the press release issued on October 30 (local time) by Bristol Myers Squibb, our license partner for Opdivo. Please click https://www.bms.com/media/press-releases.html for the original press release.
The release as fetched from its publisher. ono-pharma.com ↗